News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bioxel Pharma (BIP.V) Grants Options to its New President and Chief Executive Officer



8/12/2008 8:32:46 AM

SAINTE-FOY, QUEBEC--(Marketwire - August 12, 2008) - Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, announces that upon the signing of the employment contract of Olivier Meyer as President and Chief Executive Officer effective July 16, 2008, the Corporation's Board of Directors granted him 150,000 stock options at a price of $0.11 per option and expiring July 15, 2013.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES